Adverse effects: nystagmus Duration of treatment (range): 16–18 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy
It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant generalised tonic‐clonic seizures
It is very uncertain whether add‐on lamotrigine changes treatment withdrawal compared with placebo (very low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Oxcarbazepine probably leads to higher treatment withdrawal compared with control (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Topiramate leads to higher treatment withdrawal compared with placebo (high certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Tiagabine probably leads to higher treatment withdrawal compared with placebo control (moderate certainty).
1 finding from 1 review
Treatment withdrawal · patients with drug‐resistant epilepsy
1 finding from 1 review
Withdrawals due to adverse events · patients with drug‐resistant epilepsy
1 finding from 1 review
Treatment withdrawal · patients with drug‐resistant epilepsy
Flunarizine probably leads to higher treatment withdrawal Number of withdrawals compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · patients with drug‐resistant epilepsy
Nimodipine showed no clear difference in treatment withdrawal Number of withdrawals compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (28 weeks trial period) · Patients between five and 15 years old with a diagnosis of BECTS
The intervention showed no clear difference in proportion of patients who discontinued treatment due to adverse… (low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (over 6 months trial period) · Patients between three and 10 years old with a diagnosis of BECTS
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (96 weeks trial period) · Patients with a clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who discontinued treatment due to adverse… (very low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events ( · Patients between three and 12 years old with clinical and EEG diagnosis of BECTS
The intervention showed no clear difference in proportion of patients who discontinued treatment due to adverse… (low certainty).
1 finding from 1 review
Early seizures (number of seizures) · people with traumatic head injuries
Antiepileptic drugs may leads to lower early seizures Count of events compared with placebo or standard care (low certainty).
1 finding from 1 review
Late seizures (number of seizures) · people with traumatic head injuries
It is very uncertain whether antiepileptic drugs changes late seizures Count of events compared with placebo or standard care (very low certainty).
1 finding from 1 review
All‐cause mortality · people with traumatic head injuries
It is very uncertain whether antiepileptic drugs changes all‐cause mortality compared with placebo or standard care (very low certainty).
1 finding from 1 review
Seizures · people with traumatic head injuries
1 finding from 1 review
Treatment withdrawal · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review